Both in Biotechnology
Taysha Gene Therapies vs Hemab Therapeutics Holdings
Over the past year TSHA returned −17.7% and COAG returned +5.2%; their daily moves had a correlation of 0.49.
TSHA −17.7% COAG +5.2%Growth of $1, one year, split-adjusted
| Metric | TSHA | COAG |
|---|---|---|
| Price | $4.13 | $41.45 |
| Market cap | $1.35B | $1.94B |
| Today | −2.13% | +2.55% |
| 1 month | −12.9% | +33.5% |
| 6 months | −34.8% | — |
| Year to date | −24.9% | — |
| 1 year | −17.6% | — |
| Revenue growth (YoY) | −100.0% | — |
| Gross margin | — | — |
| Net margin | — | — |
| P/E (TTM) | — | — |
| Price / sales | 245.3× | — |
| Net cash | $406.1M | $457.5M |
| Dividend yield | — | — |
| Volatility (60d) | 58.3% | — |
| Short % of float | 17.6% | 20.4% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).